Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection

NCT02413593 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02413593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
January 31, 2016
Enrollment
111 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection